GYROSCOPE THERAPEUTICS LIMITED
Gyroscope Therapeutics Limited is a biotechnology research and development business operating as a subsidiary of the life sciences investment firm Syncona Ltd.
Get an alert when GYROSCOPE THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£25M
+116.7% vs 2023
Employees
32
-68% vs 2023
Profit before tax
£262K
+100.2% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
Therefore, the financial statements have been prepared on a non-going concern basis which the directors consider to be appropriate for the above-mentioned reasons. No specific accounting policies were affected by this decision.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | — | — | — | |
| Operating profit | -£111,542,000 | £7,198,000 | +106.5% | |
| Profit before tax | -£116,527,000 | £262,000 | +100.2% | |
| Net profit | -£95,550,000 | -£14,540,000 | +84.8% | |
| Cash | — | — | — | |
| Total assets less current liabilities | -£150,325,000 | £25,135,000 | +116.7% | |
| Net assets | -£150,325,000 | £25,135,000 | +116.7% | |
| Equity | -£150,325,000 | £25,135,000 | +116.7% | |
| Average employees | 100 | 32 | -68% | |
| Wages | £12,475,000 | £3,301,000 | -73.5% | |
| Directors' remuneration | £729,000 | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | — | 28.6% | |
| Interest cover | -23.32x | 0.99x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“Therefore, the financial statements have been prepared on a non-going concern basis which the directors consider to be appropriate for the above-mentioned reasons. No specific accounting policies were affected by this decision.”
Significant events
- “On September 6, 2023, Novartis AG announced the discontinuation of the PPY988 (GT005) development program in geographic atrophy (GA), including wind down of active studies. (Page 4)”
- “During 2024, the Company completed the sale of its IP for GBP 18.1m, resulting in a net gain of GBP 13m. (Page 4)”
- “A GBP 33.1m payable to Gyroscope Therapeutics Holding Ltd. was formally waived during 2024; income recognised within other operating income. (Page 4)”
- “On 14 December 2024, board decided to transfer business (except office lease) to Novartis Pharmaceuticals UK Limited; agreement signed 17 June 2025. (Page 5, 28)”
- “During 2024, research and development expenses reduced to £9.6m (2023: £28.4m) due to discontinuation of programs (FYH474 - GT011 and CYE472-GT013) earlier in 2023. (Page 4)”
- “The Company received a capital contribution of GBP 190m from its parent undertaking, Novartis Pharma AG, recognised directly in equity. (Page 14)”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 27 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CULLEN, Richard Samuel | Secretary | 2026-01-01 | — | — |
| BHATT, Chinmay Umesh | Director | 2023-11-14 | Oct 1973 | Dutch |
| GUPTA, Sandeep | Director | 2025-05-12 | Jun 1982 | Indian |
| KAHLSTROEM, Johan Mikael Olof | Director | 2024-11-01 | Jul 1980 | Swedish |
Show 27 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CULLEN, Richard Samuel | Secretary | 2022-02-17 | 2022-07-20 |
| JOHNSTON, Elaine | Secretary | 2021-10-04 | 2022-02-17 |
| ROBINSON, Timothy William | Secretary | 2022-07-20 | 2026-01-01 |
| OLSWANG COSEC LIMITED | Corporate Secretary | 2016-04-18 | 2021-10-04 |
| BEKKALI, Soraya, Dr | Director | 2017-07-12 | 2019-07-31 |
| BHATT, Chinmay Umesh | Director | 2022-02-17 | 2022-05-31 |
| BOHEN, Sean | Director | 2020-09-07 | 2021-10-01 |
| BROOKS, Jason Mark | Director | 2022-02-17 | 2025-04-08 |
| CLARK, Ian Thornton | Director | 2019-03-26 | 2021-10-15 |
| CLARK, Ian Thornton | Director | 2019-03-26 | 2019-08-30 |
| COOK, Jennifer Elizabeth | Director | 2020-11-01 | 2021-09-30 |
| FAROOQ, Khurem | Director | 2019-03-26 | 2021-10-04 |
| FELLOWS, David | Director | 2020-12-01 | 2021-10-01 |
| GALA, Renee | Director | 2020-11-01 | 2021-10-10 |
| GAMACHE, Marie-Andree Renee | Director | 2022-06-29 | 2024-10-31 |
| GROENDAHL, Christian, Dr | Director | 2016-04-18 | 2016-04-18 |
| HOLLOWOOD, Dr Christopher, Dr | Director | 2016-04-18 | 2021-09-29 |
| HOPKINS, Janet Jill, Dr | Director | 2022-02-17 | 2023-10-13 |
| JOUSTRA, Wouter Sebastiaan Johannes | Director | 2021-03-29 | 2021-10-08 |
| KATABI, Maha, Dr | Director | 2021-03-29 | 2021-10-10 |
| KAVANAGH, David | Director | 2016-05-12 | 2019-02-04 |
| MCANALLY, Gerard David, Dr | Director | 2021-10-04 | 2022-02-17 |
| PRENER, Anne | Director | 2017-07-12 | 2019-04-01 |
| PROSSER, Andrew Michael James | Director | 2021-10-04 | 2022-02-17 |
| SCHMIDT, Dominic, Dr | Director | 2019-02-14 | 2021-03-29 |
| THOMAS, Iain Paul, Dr | Director | 2017-07-12 | 2019-08-30 |
| WALSH, Andy Peter | Director | 2016-05-12 | 2017-07-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Gyroscope Therapeutics Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-04-15 | Active |
| Syncona Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2017-03-24 | Ceased 2021-04-15 |
Filing timeline
Last 20 of 182 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-05 | AP03 | officers | Appoint person secretary company with name date | |
| 2026-01-05 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-09-10 | AA | accounts | Accounts with accounts type full | |
| 2025-05-13 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-04-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-01-14 | CH01 | officers | Change person director company with change date | |
| 2024-11-05 | AP01 | officers | Appoint person director company with name date | |
| 2024-11-04 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-14 | AA | accounts | Accounts with accounts type full | |
| 2024-09-17 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-04-23 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-16 | AP01 | officers | Appoint person director company with name date | |
| 2023-11-14 | AA | accounts | Accounts with accounts type full | |
| 2023-10-17 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-01 | CH01 | officers | Change person director company with change date | |
| 2023-08-04 | AD03 | address | Move registers to sail company with new address | |
| 2023-08-04 | AD02 | address | Change sail address company with new address | |
| 2023-05-02 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.